Anirudh Wable Head of Corporate Development & Strategy AMPLIFY HEALTH

Anirudh has 15 years of experience across management consulting, investment banking and corporate development, with a focus on the healthcare sector. Currently, Anirudh is the Head of Corporate Development & Strategy at Amplify Health ). In this role, he is responsible for leading all investment activities, joint ventures and business partnerships to accelerate the expansion of the business operations in Asia.

Before joining RSDH, Anirudh worked with Credit Suisse in Singapore. He was a Director in the Southeast Asia Corporate Finance team and involved in the origination and execution of M&A, financing and capital market transactions. He was also responsible for leading healthcare client coverage in the Southeast Asia region. Previously, he was with Credit Suisse in New York as a Vice President in the Healthcare Investment Banking Group. Prior to Credit Suisse, Anirudh was a management consultant with PRTM / PricewaterhouseCoopers in their U.S. Life Sciences Industry Group.

Anirudh received a Master of Business Administration degree with concentrations in Finance and Accounting from The University of Chicago, Booth School of Business and earned a Bachelor of Science, Electrical Engineering degree from the University of Michigan, Ann Arbor.

Bernard Ng Chief Scientific Officer MILLTRUST VENTURES

Dr Bernard Ng serves as the Chief Scientific Officer of Milltrust Ventures Pte Ltd, a subsidiary of Milltrust International Group.

He is an angel investor and a successful professional in the field of medical and clinical affairs globally. He have had leadership roles with global and regional experience in the healthcare industry, leading teams in US, Europe and Asia. He was previously the Chief Medical Officer, Head of Medical Strategy and Clinical Development for Bayer Consumer Healthcare and an active proponent of leveraging digital technologies and data to create disproportionate value for healthcare professionals, patients and consumers with experience in leading digital transformation initiatives and due diligence for M&A.

Dr Ng was on the Investment Advisory Committee  for the British Innovation Fund (BIF), partnering with the leading Universities and Centres of Innovation in the UK to build a successful portfolio of early-stage companies. Notable successes include Vaccitech, the University of Oxford AZ vaccine company which listed on NASDAQ in 2021. He also serves on the investment committee of Future Health fund, seeking to tap into the secular growth trends in healthcare by investing in high potential companies with a focus on the science of ageing and technology that enables early detection and management of illness, leading to better outcomes in the key areas of immunization, diagnostics, telehealth, medical devices, mental health, artificial intelligence and sustainable food & proteins

In addition to his Milltrust affiliations, Dr Ng is also the Chief Executive Officer Meta Health Ltd, a listed company on the Singapore exchange who has recently diversified into healthcare technology and services. He is also a visiting lecture with the Dept of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine at King’s College London. He sits on the advisory boards of promising startups like Oncoshot and Safespace.

Dr Ng obtained his Doctor of Medicine from the National University of Malaysia and his MBA from the University of Melbourne. He is a strong believer of the Disruptive Strategy model by the Clayton Christensen from Harvard Business School He also was in IMD, Lausanne for a digital transformation course to better understand the disruptive power of platforms in today’s competitive environment

Nishtha Kharb Legal Advisor to the Board, WIPO Mediator DLT LEDGERS

Nishtha is a distinguished technology & innovation focused lawyer with over 16 years of experience in handling complex legal and regulatory issues, particularly in the Asia region.  She is presently the Chief Legal Officer at MBK Healthcare Management, a wholly owned subsidiary of Mitsui & Co with a mandate to grow the healthcare ecosystem of Mitsui with investments in leading healthcare providers such as IHH.  She has been nominated among a select panel of UN WIPO’s Neutral (Arbitrator/Mediator) in Asia. Previously, in her role of Legal Director, ASEAN, Japan & Korea at Reckitt, she managed legal affairs contributing towards innovative solutions to people’s everyday challenges in the arena of health and well-being.

 As Legal Head of Asia for another dynamic, US head-quartered health-tech company, Carestream Health Inc, a portfolio company of a USD44-Billion private-equity firm, Onyx, she successfully contributed to the company’s journey to become the Asia’s preferred innovative solution provider in the digital health space. Prior to joining Carestream, she was the in-house counsel and Data Privacy Officer at Philips Electronics Pte Ltd for ASEAN and South-East Asia operations and lead lawyer for Philips Innovation and Development Asia. She started her career as a dispute lawyer of world’s leading dispute law firm, Herbert Smith where she worked on some of the most complex cross border disputes. She was one of the youngest to be appointed as co-head of India desk at Herbert Smith’s Singapore office.  She has also held Board position in the Singapore chapter of the Association of Corporate Counsel (ACC), one of the world’s largest professional association of in-house counsels. 

A prominent thought leader and avid contributor to public policy debates shaping the future of  health- tech, intellectual property, data privacy and use of AI by legal sector, Nishtha has been speaking and moderating at various international conferences. She has been mentoring start-ups and acting as an evangelist to help shape the digital future of the legal profession.

She graduated with First Class Honours (LL.B) and also holds a Masters’ degree in law. She has completed Executive Programs on Strategy and Negotiations at Harvard University, Strategic Management Program from NUS Business School. She feels strongly about charitable causes and utilizing creative arts as a medium for contributing to society. To this end, she has directed   numerous plays, scripted and directed a music album with an aim to raise funds for blind school children and for palliative care children in Singapore. She is ever willing to be a drop in an ocean called change for good!

Navjeewan Khosla Partner NOVO HOLDINGS

Nav joined Novo Holdings Asia in August 2021 as Principal. He focuses on deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in China, India, and Southeast Asia.

Prior to joining Novo Holdings Asia, Nav was a Director in Quadria Capital, a mid-market private equity firm focusing on healthcare investments in India and South East Asia. Before joining Quadria Capital, Nav was the Managing Director at Fosun, where he worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Nav started his investment career with Merrill Lynch in Hong Kong and moved to UBS Global Asset Management in Singapore before joining Fosun.

Nav holds an MBA from Indian Institute of Management (IIM), Ahmedabad, in India and Bachelor of Technology from Indian institute of Technology (IIT), Kharagpur in India.

Beia Latay COO; Director KONSULTA MD; AYALA HEALTHCARE

Beia is the Chief Operating Officer of KonsultaMD, the Philippines’ largest healthtech company and most accessible primary care platform with over 2.5 million user base.

She played an instrumental role in establishing Ayala Corporation’s healthcare arm, AC Health, serving as Head of Strategy during its first few years. She led various portfolio investments, including Generika Drugstore, a national chain of over 800 community pharmacies. She eventually joined Generika’s Management Committee and led its Strategy, Innovation & Technology Management Group.

Beia is also a Board Director of AHCHI Pharma Ventures, Healthway Philippines and Vigos Ventures.

 Beia completed her postgraduate studies in Strategy and Innovation at Oxford University. She earned her master’s degree in Finance and Investment at the University of Edinburgh, where she was a British Chevening Scholar. She received her undergraduate degree in Management of Applied Chemistry from the Ateneo de Manila University